Quantcast
Last updated on April 18, 2014 at 5:21 EDT

Latest Quinazolines Stories

2013-10-21 10:09:54

The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23. Mutations in the growth factor gene EGFR are present in about 10 to 15 percent of patients with the most common form of lung...

2013-10-16 23:23:56

Reportbuyer.com just published a new market research report: PharmaPoint: Non-Small Cell Lung Cancer - China Drug Forecast and Market Analysis to 2022. London (PRWEB) October 16, 2013 PharmaPoint: Non-Small Cell Lung Cancer - China Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch...

2013-10-07 08:25:26

SEATTLE, WA, Oct. 7, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the presentation of final results from the first Phase 1 trial of ONT-380 at the American Association for Cancer Research Special Conference on Advances in Breast Cancer Research in San Diego. The results were presented by Virginia F. Borges, M.D., Associate Professor in the Division of Medical Oncology, University of Colorado School of Medicine. ONT-380 (also known as ARRY-380) is an orally...

2013-09-30 04:22:27

ANTWERP, Belgium, September 30, 2013 /PRNewswire/ -- Multiplicom NV, a specialist in the development, production and commercialization of innovative molecular genetic tests based on massively parallel sequencing (MPS), today announces that it is launching three new somatic mutation detection kits which will enable users to implement personalized cancer treatment at an unprecedented level. The new kits enable PCR amplification of genes known to be frequently mutated in...

2013-08-22 12:27:40

RIDGEFIELD, Conn., Aug. 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. has announced that Gilotrif(TM) (afatinib) tablets for oral use will be commercially available in the U.S. the week of September 2. The U.S. Food and Drug Administration (FDA) approved GILOTRIF on July 12, 2013 as a new first-line -- or initial -- treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an...

2013-08-07 10:44:28

New findings could lead to drugs that fight back when tumors don't respond to treatment Cancer drugs known as ErbB inhibitors have shown great success in treating many patients with lung, breast, colon and other types of cancer. However, ErbB drug resistance means that many other patients do not respond, and even among those who do, tumors commonly come back. A new study from MIT reveals that much of this resistance develops because a protein called AXL helps cancer cells to circumvent...

2013-07-26 11:16:52

Testing dropped once funding from pharmaceutical industry was discontinued Significant advances have taken place in the management of patients with advanced and metastatic non–small-cell lung cancer (NSCLC) over the last 5 years. Traditionally, all advanced NSCLC patients were treated in a similar manner. More recently, the importance of pathologic subtype has been recognized. Data from several randomized trials demonstrate that epidermal growth factor (EGFR) mutation...

2013-07-12 20:20:34

Approval supported by one of the largest Phase III trials in patients with EGFR mutation-positive advanced NSCLC RIDGEFIELD, Conn., July 12, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved GILOTRIF(TM) (afatinib) tablets for oral use, as a new first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR)...

2013-07-12 12:25:18

GERMANTOWN, Maryland, and HILDEN, Germany, July 12, 2013 /PRNewswire/ -- - U.S. launch of therascreen EGFR RGQ PCR Kit (therascreen EGFR test) follows FDA approval of system to select non-small cell lung cancer (NSCLC) patients eligible for treatment with GILOTRIF(TM) (afatinib) - therascreen EGFR test addresses high volume, high value need with the broadest coverage of validated mutations - Patients and healthcare...

2013-06-27 23:20:05

BioPlus selected as a specialty pharmacy for the new Tarceva network; now authorized to dispense this oncology medication. Altamonte Springs, FL (PRWEB) June 27, 2013 The medication Tarceva® (erlotinib) from Genentech and Astellas Pharma US, Inc. will no longer be distributed through retail pharmacies, effective July 1, 2013. Tarceva will be supplied through BioPlus Specialty Pharmacy (BioPlus) and other select specialty pharmacies. Tarceva is a once daily oral non-chemotherapy...